Seqens Seqens

X
[{"orgOrder":0,"company":"Xellia Pharmaceuticals ApS","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eton Pharmaceuticals and Xellia Pharmaceuticals Announce Biorphen\u00ae (phenylephrine HCl) Co-Promotion Agreement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Xellia Pharmaceuticals ApS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xellia Pharmaceuticals expands approved doses of VANCO READY\u2122 (Ready-to-use Premixed Vancomycin bags)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Xellia Pharmaceuticals ApS

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Xellia Pharmaceuticals has received approval for 3 additional dosages of VANCO READY™, expanding its range of room-temperature-stable, ready-to-use (RTU) Vancomycin injection premix bags.

            Lead Product(s): Vancomycin Hydrochloride

            Therapeutic Area: Infections and Infectious Diseases Product Name: Vanco Ready

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 02, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Agreement significantly expands biorphen commercial footprint and provides access to institutions that prefer ready-to-use injectable formulations.

            Lead Product(s): Phenylephrine HCl

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: Eton Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 21, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY